The proposed compensation package is way too gener
Post# of 148343
the options and CYDY stock he already has are already excessive. Thus far he is has not proven himself to be an effective CEO.
A small clinical stage OTC with no sales, no FDA approvals, that is in it's "prove it" phase should not rewarding an already overcompensated CEO and his suspect BOD.